A French startup has raised $8.7 million that it’ll use to advance large-scale manufacturing of therapies based mostly on the human microbiome, a teeming world of micro organism seen as a key to higher well being.
Based in 2014, Lyon, France-based MaaT Pharma makes therapies designed to revive a affected person’s microbiome to enhance the percentages of survival within the face of most cancers and different illnesses.
The corporate has two therapies in scientific trials, one for sufferers with blood cancers and one for graft-versus-host illness, a typical complication following stem-cell or bone-marrow transplants.
“We plan to broaden into extra oncological indications the place restoring or modulating the intestine microbiome might present important therapeutic profit when mixed with different most cancers therapies,” Maat Pharma co-founder and CEO Hervé Affagard wrote in an emailed response to questions forwarded by an organization spokesperson.
The MaaT Pharma remedy farthest alongside the clinical-trial path is called MaaT013, at present made in an enema type. The remedy is being evaluated in a Section II trial for security and efficacy in sufferers with steroid-refractory intestine predominant acute graft-versus-host illness. Topline knowledge is anticipated early subsequent yr, Affagard wrote.
The second remedy, MaaT033, entered a Section I trial in November. Obtainable in capsule type, it’s designed to revive performance of the intestine system to enhance scientific outcomes and management opposed occasions associated to standard therapies for most cancers, Affagard wrote. The trial is targeted on sufferers with acute myeloid leukemia or high-risk myelodysplastic syndrome following intensive chemotherapy. Preliminary outcomes are anticipated in late 2021, Affagard stated.
MaaT Pharma is also producing MaaT013 for graft-versus-host illness sufferers beneath a compassionate-use program in France. To date, 41 sufferers have obtained the remedy. The corporate plans to current scientific knowledge from 29 of these sufferers on the annual assembly of the American Society of Hematology, set for Dec. 6, Affagard wrote.
The brand new $8.7 million funding – an prolonged Collection B spherical – will assist manufacturing of therapies for compassionate use, in addition to development of a large-scale fermentation manufacturing platform for microbiome therapeutics. MaaT Pharma employs 34 individuals.
Traders embody the PSIM Fund, which is managed by funding financial institution Bpifrance on behalf of the French authorities. Different buyers embody SkyViews Life Science and Celeste Administration.
“MaaT Pharma has developed an revolutionary portfolio of microbiome-based biotherapeutics that we consider gives super short-term and long-term potential, addressing the wants of advanced-stage most cancers sufferers with restricted choices,” Muriel Prudent, senior funding supervisor at Bpifrance, stated in an announcement.
The primary leg of the Collection B spherical closed in February after elevating about $20.8 million. That spherical was led by SymBiosis LLC, with participation from Seventure Companions, Crédit Mutuel Innovation and Biocodex.
Firms targeted on the microbiome stay enticing to buyers regardless of the 2019 scandal engulfing one of many discipline’s best-known startups, uBiome.
Final month, ADM Ventures, the enterprise capital arm of Chicago-based meals large Archer Daniels Midland, made an undisclosed funding in a Seventure fund targeted on well being, diet, microbiota and digital well being.
“With a greater understanding of how the microbiome ecosystem works, we will develop purposeful substances for dietary dietary supplements and meals and beverage options focused to assist enhance general well being,” Darren Streiler, managing director of ADM Ventures, stated in an announcement on the time. “We’re targeted on taking a look at new, revolutionary options that may result in a extra balanced bacterial system in your digestive tract, in any other case generally known as a wholesome intestine, and may help result in higher well being.”